How addictive are gabapentin and pregabalin? A systematic review

In the last ten years, gabapentin and pregabalin have been becoming dispensed broadly and sold on black markets, thereby, exposing millions to potential side-effects. Meanwhile, several pharmacovigilance-databases have warned for potential abuse liabilities and overdose fatalities in association wit...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European neuropsychopharmacology 2017-12, Vol.27 (12), p.1185-1215
Hauptverfasser: Bonnet, U., Scherbaum, N.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1215
container_issue 12
container_start_page 1185
container_title European neuropsychopharmacology
container_volume 27
creator Bonnet, U.
Scherbaum, N.
description In the last ten years, gabapentin and pregabalin have been becoming dispensed broadly and sold on black markets, thereby, exposing millions to potential side-effects. Meanwhile, several pharmacovigilance-databases have warned for potential abuse liabilities and overdose fatalities in association with both gabapentinoids. To evaluate their addiction risk in more detail, we conducted a systematic review on PubMed/Scopus and included 106 studies. We did not find convincing evidence of a vigorous addictive power of gabapentinoids which is primarily suggested from their limited rewarding properties, marginal notes on relapses, and the very few cases with gabapentinoid-related behavioral dependence symptoms (ICD-10) in patients without a prior abuse history (N=4). In support, there was no publication about people who sought treatment for the use of gabapentinoids. Pregabalin appeared to be somewhat more addictive than gabapentin regarding the magnitude of behavioral dependence symptoms, transitions from prescription to self-administration, and the durability of the self-administrations. The principal population at risk for addiction of gabapentinoids consists of patients with other current or past substance use disorders (SUD), mostly opioid and multi-drug users, who preferred pregabalin. Pure overdoses of gabapentinoids appeared to be relative safe but can become lethal (pregabalin > gabapentin) in mixture with other psychoactive drugs, especially opioids again and sedatives. Based upon these results, we compared the addiction risks of gabapentin and pregabalin with those of traditional psychoactive substances and recommend that in patients with a history of SUD, gabapentinoids should be avoided or if indispensable, administered with caution by using a strict therapeutic and prescription monitoring.
doi_str_mv 10.1016/j.euroneuro.2017.08.430
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1949086243</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0924977X17308970</els_id><sourcerecordid>1949086243</sourcerecordid><originalsourceid>FETCH-LOGICAL-c437t-207777d62e1fed751da8625a7100e5ddf2eaeab532a87fa6ec7e9eecb92b5a53</originalsourceid><addsrcrecordid>eNqFkE1PwzAMhiMEYmPwF6BHLi35aJvmBNMEDGkSlx24RWniokz9GEm7af-eVBu74oMtWa_92g9CDwQnBJP8aZPA4Lp2TAnFhCe4SFKGL9CUFJzFvMjpJZpiQdNYcP41QTfebzAmGWPiGk1oIYpCpGyKXpbdPlLGWN3bHUTKQfStSrWFtrdtpFoTbR2Mndq2z9E88gffQ6N6qyMHOwv7W3RVqdrD3anO0Prtdb1YxqvP94_FfBXrlPE-ppiHMDkFUoHhGTEq3JgpTjCGzJiKggJVZoyqglcqB81BAOhS0DJTGZuhx-Paret-BvC9bKzXUNeqhW7wkohU4LAxZUHKj1LtOu8dVHLrbKPcQRIsR3pyI8_05EhP4kIGemHy_mQylA2Y89wfriCYHwUQPg3fO-m1hVaDsQ50L01n_zX5BdKHhlw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1949086243</pqid></control><display><type>article</type><title>How addictive are gabapentin and pregabalin? A systematic review</title><source>Access via ScienceDirect (Elsevier)</source><creator>Bonnet, U. ; Scherbaum, N.</creator><creatorcontrib>Bonnet, U. ; Scherbaum, N.</creatorcontrib><description>In the last ten years, gabapentin and pregabalin have been becoming dispensed broadly and sold on black markets, thereby, exposing millions to potential side-effects. Meanwhile, several pharmacovigilance-databases have warned for potential abuse liabilities and overdose fatalities in association with both gabapentinoids. To evaluate their addiction risk in more detail, we conducted a systematic review on PubMed/Scopus and included 106 studies. We did not find convincing evidence of a vigorous addictive power of gabapentinoids which is primarily suggested from their limited rewarding properties, marginal notes on relapses, and the very few cases with gabapentinoid-related behavioral dependence symptoms (ICD-10) in patients without a prior abuse history (N=4). In support, there was no publication about people who sought treatment for the use of gabapentinoids. Pregabalin appeared to be somewhat more addictive than gabapentin regarding the magnitude of behavioral dependence symptoms, transitions from prescription to self-administration, and the durability of the self-administrations. The principal population at risk for addiction of gabapentinoids consists of patients with other current or past substance use disorders (SUD), mostly opioid and multi-drug users, who preferred pregabalin. Pure overdoses of gabapentinoids appeared to be relative safe but can become lethal (pregabalin &gt; gabapentin) in mixture with other psychoactive drugs, especially opioids again and sedatives. Based upon these results, we compared the addiction risks of gabapentin and pregabalin with those of traditional psychoactive substances and recommend that in patients with a history of SUD, gabapentinoids should be avoided or if indispensable, administered with caution by using a strict therapeutic and prescription monitoring.</description><identifier>ISSN: 0924-977X</identifier><identifier>EISSN: 1873-7862</identifier><identifier>DOI: 10.1016/j.euroneuro.2017.08.430</identifier><identifier>PMID: 28988943</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Abuse potential ; Gabapentin ; Liking ; Overdose fatalities ; Pregabalin ; Wanting</subject><ispartof>European neuropsychopharmacology, 2017-12, Vol.27 (12), p.1185-1215</ispartof><rights>2017 Elsevier B.V. and ECNP</rights><rights>Copyright © 2017 Elsevier B.V. and ECNP. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c437t-207777d62e1fed751da8625a7100e5ddf2eaeab532a87fa6ec7e9eecb92b5a53</citedby><cites>FETCH-LOGICAL-c437t-207777d62e1fed751da8625a7100e5ddf2eaeab532a87fa6ec7e9eecb92b5a53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.euroneuro.2017.08.430$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28988943$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bonnet, U.</creatorcontrib><creatorcontrib>Scherbaum, N.</creatorcontrib><title>How addictive are gabapentin and pregabalin? A systematic review</title><title>European neuropsychopharmacology</title><addtitle>Eur Neuropsychopharmacol</addtitle><description>In the last ten years, gabapentin and pregabalin have been becoming dispensed broadly and sold on black markets, thereby, exposing millions to potential side-effects. Meanwhile, several pharmacovigilance-databases have warned for potential abuse liabilities and overdose fatalities in association with both gabapentinoids. To evaluate their addiction risk in more detail, we conducted a systematic review on PubMed/Scopus and included 106 studies. We did not find convincing evidence of a vigorous addictive power of gabapentinoids which is primarily suggested from their limited rewarding properties, marginal notes on relapses, and the very few cases with gabapentinoid-related behavioral dependence symptoms (ICD-10) in patients without a prior abuse history (N=4). In support, there was no publication about people who sought treatment for the use of gabapentinoids. Pregabalin appeared to be somewhat more addictive than gabapentin regarding the magnitude of behavioral dependence symptoms, transitions from prescription to self-administration, and the durability of the self-administrations. The principal population at risk for addiction of gabapentinoids consists of patients with other current or past substance use disorders (SUD), mostly opioid and multi-drug users, who preferred pregabalin. Pure overdoses of gabapentinoids appeared to be relative safe but can become lethal (pregabalin &gt; gabapentin) in mixture with other psychoactive drugs, especially opioids again and sedatives. Based upon these results, we compared the addiction risks of gabapentin and pregabalin with those of traditional psychoactive substances and recommend that in patients with a history of SUD, gabapentinoids should be avoided or if indispensable, administered with caution by using a strict therapeutic and prescription monitoring.</description><subject>Abuse potential</subject><subject>Gabapentin</subject><subject>Liking</subject><subject>Overdose fatalities</subject><subject>Pregabalin</subject><subject>Wanting</subject><issn>0924-977X</issn><issn>1873-7862</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNqFkE1PwzAMhiMEYmPwF6BHLi35aJvmBNMEDGkSlx24RWniokz9GEm7af-eVBu74oMtWa_92g9CDwQnBJP8aZPA4Lp2TAnFhCe4SFKGL9CUFJzFvMjpJZpiQdNYcP41QTfebzAmGWPiGk1oIYpCpGyKXpbdPlLGWN3bHUTKQfStSrWFtrdtpFoTbR2Mndq2z9E88gffQ6N6qyMHOwv7W3RVqdrD3anO0Prtdb1YxqvP94_FfBXrlPE-ppiHMDkFUoHhGTEq3JgpTjCGzJiKggJVZoyqglcqB81BAOhS0DJTGZuhx-Paret-BvC9bKzXUNeqhW7wkohU4LAxZUHKj1LtOu8dVHLrbKPcQRIsR3pyI8_05EhP4kIGemHy_mQylA2Y89wfriCYHwUQPg3fO-m1hVaDsQ50L01n_zX5BdKHhlw</recordid><startdate>201712</startdate><enddate>201712</enddate><creator>Bonnet, U.</creator><creator>Scherbaum, N.</creator><general>Elsevier B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201712</creationdate><title>How addictive are gabapentin and pregabalin? A systematic review</title><author>Bonnet, U. ; Scherbaum, N.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c437t-207777d62e1fed751da8625a7100e5ddf2eaeab532a87fa6ec7e9eecb92b5a53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Abuse potential</topic><topic>Gabapentin</topic><topic>Liking</topic><topic>Overdose fatalities</topic><topic>Pregabalin</topic><topic>Wanting</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bonnet, U.</creatorcontrib><creatorcontrib>Scherbaum, N.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European neuropsychopharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bonnet, U.</au><au>Scherbaum, N.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>How addictive are gabapentin and pregabalin? A systematic review</atitle><jtitle>European neuropsychopharmacology</jtitle><addtitle>Eur Neuropsychopharmacol</addtitle><date>2017-12</date><risdate>2017</risdate><volume>27</volume><issue>12</issue><spage>1185</spage><epage>1215</epage><pages>1185-1215</pages><issn>0924-977X</issn><eissn>1873-7862</eissn><abstract>In the last ten years, gabapentin and pregabalin have been becoming dispensed broadly and sold on black markets, thereby, exposing millions to potential side-effects. Meanwhile, several pharmacovigilance-databases have warned for potential abuse liabilities and overdose fatalities in association with both gabapentinoids. To evaluate their addiction risk in more detail, we conducted a systematic review on PubMed/Scopus and included 106 studies. We did not find convincing evidence of a vigorous addictive power of gabapentinoids which is primarily suggested from their limited rewarding properties, marginal notes on relapses, and the very few cases with gabapentinoid-related behavioral dependence symptoms (ICD-10) in patients without a prior abuse history (N=4). In support, there was no publication about people who sought treatment for the use of gabapentinoids. Pregabalin appeared to be somewhat more addictive than gabapentin regarding the magnitude of behavioral dependence symptoms, transitions from prescription to self-administration, and the durability of the self-administrations. The principal population at risk for addiction of gabapentinoids consists of patients with other current or past substance use disorders (SUD), mostly opioid and multi-drug users, who preferred pregabalin. Pure overdoses of gabapentinoids appeared to be relative safe but can become lethal (pregabalin &gt; gabapentin) in mixture with other psychoactive drugs, especially opioids again and sedatives. Based upon these results, we compared the addiction risks of gabapentin and pregabalin with those of traditional psychoactive substances and recommend that in patients with a history of SUD, gabapentinoids should be avoided or if indispensable, administered with caution by using a strict therapeutic and prescription monitoring.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>28988943</pmid><doi>10.1016/j.euroneuro.2017.08.430</doi><tpages>31</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0924-977X
ispartof European neuropsychopharmacology, 2017-12, Vol.27 (12), p.1185-1215
issn 0924-977X
1873-7862
language eng
recordid cdi_proquest_miscellaneous_1949086243
source Access via ScienceDirect (Elsevier)
subjects Abuse potential
Gabapentin
Liking
Overdose fatalities
Pregabalin
Wanting
title How addictive are gabapentin and pregabalin? A systematic review
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T04%3A01%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=How%20addictive%20are%20gabapentin%20and%20pregabalin?%20A%20systematic%20review&rft.jtitle=European%20neuropsychopharmacology&rft.au=Bonnet,%20U.&rft.date=2017-12&rft.volume=27&rft.issue=12&rft.spage=1185&rft.epage=1215&rft.pages=1185-1215&rft.issn=0924-977X&rft.eissn=1873-7862&rft_id=info:doi/10.1016/j.euroneuro.2017.08.430&rft_dat=%3Cproquest_cross%3E1949086243%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1949086243&rft_id=info:pmid/28988943&rft_els_id=S0924977X17308970&rfr_iscdi=true